WO2009033819A3 - Utilisation d'un peptide en tant qu'agent thérapeutique - Google Patents
Utilisation d'un peptide en tant qu'agent thérapeutique Download PDFInfo
- Publication number
- WO2009033819A3 WO2009033819A3 PCT/EP2008/008187 EP2008008187W WO2009033819A3 WO 2009033819 A3 WO2009033819 A3 WO 2009033819A3 EP 2008008187 W EP2008008187 W EP 2008008187W WO 2009033819 A3 WO2009033819 A3 WO 2009033819A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ser
- asp
- pro
- combination
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Marine Sciences & Fisheries (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne l'utilisation de la combinaison des composés peptidiques Lys-Phe-Arg- Arg-Ser-Leu-Gln-Asp-Thr-Glu-Glu-Lys-Ser-Arg-Ser-Phe-Ser-Ala-Ser- Gln-Ala-Asp-Pro-Leu-Ser-Asp-Pro-Asp-Gln-Met-Asn-Glu-Asp-OH et Gln-Arg-Pro- Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe-OH en tant que composés polythérapeutiques destinés à la prophylaxie et/ou au traitement du cancer, d'une maladie cardiaque et vasculaire, d'une maladie infectieuse, d'une maladie fibreuse, d'une maladie inflammatoire, d'une maladie neurodégénérative ou d'une maladie auto-immune.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07017749.8 | 2007-09-11 | ||
EP07017766 | 2007-09-11 | ||
EP07017749 | 2007-09-11 | ||
EP07017766.2 | 2007-09-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009033819A2 WO2009033819A2 (fr) | 2009-03-19 |
WO2009033819A3 true WO2009033819A3 (fr) | 2009-11-05 |
Family
ID=40452600
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2008/008187 WO2009033819A2 (fr) | 2007-09-11 | 2008-09-09 | Utilisation d'un peptide en tant qu'agent thérapeutique |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009033819A2 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8673848B2 (en) | 2012-01-27 | 2014-03-18 | Novartis Ag | Synthetic apelin mimetics for the treatment of heart failure |
EP2785365B1 (fr) | 2011-11-28 | 2017-07-19 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Composition pharmaceutique à utiliser dans le traitement des dysfonctionnements liés au vieillissement |
US8921307B2 (en) | 2012-11-20 | 2014-12-30 | Novartis Ag | Synthetic linear apelin mimetics for the treatment of heart failure |
UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
TN2016000031A1 (en) | 2013-07-25 | 2017-07-05 | Novartis Ag | Cyclic polypeptides for the treatment of heart failure |
KR20160031552A (ko) | 2013-07-25 | 2016-03-22 | 노파르티스 아게 | 합성 아펠린 폴리펩티드의 생체접합체 |
CN104436158A (zh) * | 2013-09-22 | 2015-03-25 | 华中科技大学 | Apelin-13在治疗糖尿病肾病中的应用 |
CN114099637A (zh) * | 2021-12-15 | 2022-03-01 | 广东省职业病防治院(广东省职业卫生检测中心) | Apelin在制备治疗矽肺的药物中的应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4405608A (en) * | 1980-08-28 | 1983-09-20 | Novo Industri A/S | Novel peptide |
EP1116727A1 (fr) * | 1998-09-25 | 2001-07-18 | Takeda Chemical Industries, Ltd. | Derive de peptide |
WO2004081198A2 (fr) * | 2003-03-12 | 2004-09-23 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Procedes de modulation de l'angiogenese avec de compositions d'apeline |
US20050070459A1 (en) * | 2001-11-26 | 2005-03-31 | Brigham And Women"S Hospital | Methods for treating autoimmune disorders, and reagents related thereto |
US20060045880A1 (en) * | 2004-08-23 | 2006-03-02 | Krieg Paul A | Methods for modulating angiogenesis and apoptosis with apelin compositions |
-
2008
- 2008-09-09 WO PCT/EP2008/008187 patent/WO2009033819A2/fr active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4405608A (en) * | 1980-08-28 | 1983-09-20 | Novo Industri A/S | Novel peptide |
EP1116727A1 (fr) * | 1998-09-25 | 2001-07-18 | Takeda Chemical Industries, Ltd. | Derive de peptide |
US20050070459A1 (en) * | 2001-11-26 | 2005-03-31 | Brigham And Women"S Hospital | Methods for treating autoimmune disorders, and reagents related thereto |
WO2004081198A2 (fr) * | 2003-03-12 | 2004-09-23 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Procedes de modulation de l'angiogenese avec de compositions d'apeline |
US20060045880A1 (en) * | 2004-08-23 | 2006-03-02 | Krieg Paul A | Methods for modulating angiogenesis and apoptosis with apelin compositions |
Non-Patent Citations (12)
Title |
---|
HAN ET AL: "Increased colonic apelin production in rodents with experimental colitis and in humans with IBD", REGULATORY PEPTIDES, ELSEVIER SCIENCE BV, NL, vol. 142, no. 3, 14 June 2007 (2007-06-14), pages 131 - 137, XP022116452, ISSN: 0167-0115 * |
HOLST J J: "Enteroglucagon.", ANNUAL REVIEW OF PHYSIOLOGY 1997, vol. 59, 1997, pages 257 - 271, XP002540448, ISSN: 0066-4278 * |
HUI XIE ET AL: "Apelin suppresses apoptosis of human osteoblasts", APOPTOSIS ; AN INTERNATIONAL JOURNAL ON PROGRAMMED CELL DEATH, KLUWER ACADEMIC PUBLISHERS, BO, vol. 12, no. 1, 21 November 2006 (2006-11-21), pages 247 - 254, XP019463727, ISSN: 1573-675X * |
KASAI A ET AL: "Apelin is a novel angiogenic factor in retinal endothelial cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 325, no. 2, 10 December 2004 (2004-12-10), pages 395 - 400, XP004626806, ISSN: 0006-291X * |
KLEINZ M J ET AL: "Emerging roles of apelin in biology and medicine", PHARMACOLOGY AND THERAPEUTICS, ELSEVIER, GB, vol. 107, no. 2, 1 August 2005 (2005-08-01), pages 198 - 211, XP004963619, ISSN: 0163-7258 * |
LADEIRAS-LOPES RICARDO ET AL: "The apelinergic system: the role played in human physiology and pathology and potential therapeutic applications.", ARQUIVOS BRASILEIROS DE CARDIOLOGIA MAY 2008, vol. 90, no. 5, May 2008 (2008-05-01), pages 343 - 349, XP002539444, ISSN: 1678-4170 * |
LEE D K ET AL: "Unravelling the roles of the apelin system: prospective therapeutic applications in heart failure and obesity", TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER, HAYWARTH, GB, vol. 27, no. 4, 1 April 2006 (2006-04-01), pages 190 - 194, XP025029550, ISSN: 0165-6147, [retrieved on 20060401] * |
MASRI B ET AL: "Apelin signalling: a promising pathway from cloning to pharmacology", CELLULAR SIGNALLING, ELSEVIER SCIENCE LTD, GB, vol. 17, no. 4, 1 April 2005 (2005-04-01), pages 415 - 426, XP025337469, ISSN: 0898-6568, [retrieved on 20050401] * |
OHNEDA A ET AL: "EFFECT OF GLICENTIN-RELATED PEPTIDES UPON THE SECRETION OF INSULIN AND GLUCAGON IN THE CANINE PANCREAS", TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, vol. 155, no. 2, 1988, pages 197 - 204, XP002540447, ISSN: 0040-8727 * |
SAINT-GENIEZ M ET AL: "Expression of the murine msr/apj receptor and its ligand apelin is upregulated during formation of the retinal vessels", MECHANISMS OF DEVELOPMENT, ELSEVIER SCIENCE IRELAND LTD, IE, vol. 110, 1 January 2002 (2002-01-01), pages 183 - 186, XP002992963, ISSN: 0925-4773 * |
SORLI S C ET AL: "Therapeutic potential of interfering with apelin signalling", DRUG DISCOVERY TODAY, ELSEVIER, RAHWAY, NJ, US, vol. 11, no. 23-24, 1 December 2006 (2006-12-01), pages 1100 - 1106, XP025027123, ISSN: 1359-6446, [retrieved on 20061201] * |
TANG ET AL: "Apelin stimulates proliferation and suppresses apoptosis of mouse osteoblastic cell line MC3T3-E1 via JNK and PI3-K/Akt signaling pathways", PEPTIDES, ELSEVIER, AMSTERDAM, vol. 28, no. 3, 7 February 2007 (2007-02-07), pages 708 - 718, XP005877280, ISSN: 0196-9781 * |
Also Published As
Publication number | Publication date |
---|---|
WO2009033819A2 (fr) | 2009-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009033821A3 (fr) | Utilisation d'un peptide en tant qu'agent thérapeutique | |
WO2009033797A3 (fr) | Utilisation d'un peptide en tant qu'agent thérapeutique | |
WO2009043518A3 (fr) | Utilisation d'un peptide en tant qu'agent thérapeutique | |
WO2009033819A3 (fr) | Utilisation d'un peptide en tant qu'agent thérapeutique | |
LTPA2017015I1 (lt) | Apoptozę sukeliantys agentai, skirti vėžio ir imuninių ir autoimuninių ligų gydymui | |
MY161340A (en) | Apoptosis-Inducing Agents For The Treatment Of Cancer And Immune And Autoimmune Diseases | |
IL212879A0 (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
WO2006058868A3 (fr) | Pteridines substituees destinees au traitement de maladies inflammatoires | |
UA85471C2 (ru) | Применение оксикодона для лечения висцеральной боли | |
WO2009089635A9 (fr) | Traitement de maladies neurodégénératives avec de la progranuline (pgrn) | |
WO2012061390A3 (fr) | Compositions et procédés thérapeutiques | |
WO2012101156A3 (fr) | Nouveaux peptides synthétiques et leur utilisation | |
MX2013003060A (es) | Terapia de combinacion para tratar infeccion por hcv. | |
WO2009043525A3 (fr) | Utilisation d'un peptide en tant qu'agent thérapeutique | |
WO2009033820A3 (fr) | Utilisation d'un peptide en tant qu'agent thérapeutique | |
WO2009033814A3 (fr) | Utilisation d'un peptide en tant qu'agent thérapeutique | |
WO2009033813A3 (fr) | Utilisation d'un peptide en tant qu'agent thérapeutique | |
WO2009033818A3 (fr) | Utilisation d'un peptide en tant qu'agent thérapeutique | |
WO2009046875A3 (fr) | Utilisation d'un peptide en tant qu'agent thérapeutique | |
WO2009033816A3 (fr) | Utilisation d'un peptide en tant qu'agent thérapeutique | |
WO2008009426A9 (fr) | Dérivés de 5-cyano-prostacycline utilisés comme agents dans le traitement de maladies auto-immunes | |
WO2009033809A3 (fr) | Utilisation d'un peptide en tant qu'agent thérapeutique | |
WO2009043519A3 (fr) | Utilisation d'un peptide en tant qu'agent thérapeutique | |
WO2009046872A3 (fr) | Utilisation d'un peptide en tant qu'agent thérapeutique | |
WO2009043523A3 (fr) | Utilisation d'un peptide en tant qu'agent thérapeutique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08830656 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08830656 Country of ref document: EP Kind code of ref document: A2 |